Renal failure. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Control group: Administration of oral medication similar to the intervention drug once a day for 3 months. Intervention 2: Intervention group: Oral administration of a 100 mg Q 10 supp
Treatment - Drugs
Control group: Administration of oral medication similar to the intervention drug once a day for 3 months
Intervention group: Oral administration of a 100 mg Q 10 supplement (manufactured by Health Burs Corporation) once a day for 3 months
Sponsors
Vice chancellor for research, Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Main inclusion criteria: End-stage renal failure patients with diabetes who have been undergoing dialysis maintenance for at least 6 months; No smoking at the time of the study; Blood pressure less than 180-100 mm Hg when entering the study. Major exclusion criteria: Antioxidant use at the time of entry; Acute renal failure; Hepatic failure; Cancer; infection of any type(catheter infection, urinary tract infections, etc.).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum CRP level. Timepoint: At the beginning of the study and 3 months after the beginning of the study. Method of measurement: Miligram in liter.;Serum levels of homocysteine. Timepoint: At the beginning of the study and 3 months after the beginning of the study. Method of measurement: Miligram in liter.;Serum albumin level. Timepoint: At the beginning of the study and 3 months after the beginning of the study. Method of measurement: Miligram in liter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBatool Shahraki
Zahedan University of Medical Sciences
Outcome results
None listed